PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
16.91%
Revenue growth 1.25-1.5x AVGO's 12.94%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
-17.38%
Negative gross profit growth while AVGO is at 20.10%. Joel Greenblatt would examine cost competitiveness or demand decline.
52.33%
EBIT growth 1.25-1.5x AVGO's 38.46%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
52.33%
Operating income growth 1.25-1.5x AVGO's 38.46%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
47.70%
Net income growth under 50% of AVGO's 136.84%. Michael Burry would suspect the firm is falling well behind a key competitor.
48.39%
EPS growth under 50% of AVGO's 137.50%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
48.39%
Diluted EPS growth under 50% of AVGO's 131.25%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.80%
Share count expansion well above AVGO's 0.85%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.80%
Diluted share count expanding well above AVGO's 0.82%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-4.93%
Negative OCF growth while AVGO is at 180.49%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-3.21%
Negative FCF growth while AVGO is at 203.13%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
509.80%
10Y revenue/share CAGR above 1.5x AVGO's 42.48%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
55.35%
5Y revenue/share CAGR 1.25-1.5x AVGO's 42.48%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
8.55%
3Y revenue/share CAGR under 50% of AVGO's 42.48%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
2607.97%
10Y OCF/share CAGR above 1.5x AVGO's 56.67%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
526.71%
5Y OCF/share CAGR above 1.5x AVGO's 56.67%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
663.79%
3Y OCF/share CAGR above 1.5x AVGO's 56.67%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-1062.70%
Negative 10Y net income/share CAGR while AVGO is at 361.05%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-1976.89%
Negative 5Y net income/share CAGR while AVGO is 361.05%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-216.66%
Negative 3Y CAGR while AVGO is 361.05%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
1568.61%
10Y equity/share CAGR above 1.5x AVGO's 42.35%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
87.24%
5Y equity/share CAGR above 1.5x AVGO's 42.35%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
30.55%
3Y equity/share CAGR at 50-75% of AVGO's 42.35%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.63%
AR growth well above AVGO's 22.66%. Michael Burry fears inflated revenue or higher default risk in the near future.
-14.68%
Inventory is declining while AVGO stands at 7.23%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
3.77%
Asset growth well under 50% of AVGO's 9.19%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-3.85%
We have a declining book value while AVGO shows 9.47%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-1.15%
We’re deleveraging while AVGO stands at 0.43%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-36.10%
Our R&D shrinks while AVGO invests at 9.38%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-37.77%
We cut SG&A while AVGO invests at 4.35%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.